Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(19)
DRUG(8)
BIOLOGICAL(1)
Rituximab
5 trials
phase_1phase_1_2phase_2
national-cancer-institute-nci
Filgrastim
2 trials
phase_1_2phase_2
national-cancer-institute-nci
Alemtuzumab (Campath)
2 trials
phase_2
national-cancer-institute-nci
Cyclophosphamide
2 trials
phase_1phase_1_2
national-cancer-institute-nci
Etoposide
2 trials
phase_1phase_1_2
national-cancer-institute-nci
Prednisone
2 trials
phase_1phase_1_2
national-cancer-institute-nci
Doxorubicin
2 trials
phase_1phase_1_2
national-cancer-institute-nci
Vincristine
2 trials
phase_1phase_1_2
national-cancer-institute-nci

+8 more interventions

16 unique interventions3 categories

Analytics

Trial Phases

Phase 13
Phase 25

Trial Status

Completed5
Terminated1
Other1

Role Distribution

Principal Investigator7
PI Rate100%

Activity Timeline

Clinical Trials (7)

NCT01030900Phase 2Completed
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Diffuse Large B-Cell LymphomaHodgkin Lymphoma
PrincipalinvestigatorStart date: 2009-10-22
NCT01445535Phase 1Completed
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Gamma Delta Hepatosplenic T-Cell LymphomaNK T-Cell LymphomaSubcutaneous Panniculitis-Like T-Cell Lymphoma+1 more
PrincipalinvestigatorStart date: 2009-01-13
NCT00114738Phase 2Completed
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Lymphoma, Mantle CellMantle Cell Lymphoma
PrincipalinvestigatorStart date: 2005-06-15
NCT00069238Phase 2Completed
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Lymphoma, Extranodal NK-T-CellLymphoma, T-Cell
PrincipalinvestigatorStart date: 2003-09-19
NCT00001563Phase 2Completed
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
AIDS Related LymphomaAIDS-Associated Lymphoma
PrincipalinvestigatorStart date: 1997-01-08
NCT00022971Phase 1Terminated
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular Lymphoma+2 more
Principalinvestigator
NCT01415765Phase 1/2Withdrawn
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Diffuse, Large B-cell LymphomaLarge-Cell Lymphoma, DiffuseLymphoma, Diffuse Large-Cell+1 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Lymphoma, FollicularLeukemia, Lymphocytic, Chronic, B-CellHodgkin Disease+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score9%

Thomas E. Witzig, MD

Mayo Clinic

Related
12 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseSubcutaneous Panniculitis-Like T-Cell Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score7%

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Hodgkin DiseaseLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, Diffuse
Similarity Score7%

Helen Heslop, MD

Baylor College of Medicine

Related
17 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellHodgkin DiseaseLymphoma, Extranodal NK-T-Cell
Similarity Score7%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma, Mantle-Cell
Similarity Score7%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, Diffuse

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score5%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score5%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score5%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Follicular
Similarity Score5%

Carlos Montalbán Sanz, MD

Hospital Universitario Ramon y Cajal

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (7)

Showing 7 of 7 trials

NCT01030900Phase 2PrincipalInvestigator

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Diffuse Large B-Cell LymphomaHodgkin Lymphoma
Completed
NCT01445535Phase 1PrincipalInvestigator

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Gamma Delta Hepatosplenic T-Cell LymphomaNK T-Cell LymphomaSubcutaneous Panniculitis-Like T-Cell Lymphoma+1 more
Completed
NCT00114738Phase 2PrincipalInvestigator

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Lymphoma, Mantle CellMantle Cell Lymphoma
Completed
NCT00069238Phase 2PrincipalInvestigator

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

Lymphoma, Extranodal NK-T-CellLymphoma, T-Cell
Completed
NCT00001563Phase 2PrincipalInvestigator

EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma

AIDS Related LymphomaAIDS-Associated Lymphoma
Completed
NCT00022971Phase 1PrincipalInvestigator

Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular Lymphoma+2 more
Terminated
NCT01415765Phase 1/2PrincipalInvestigator

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Diffuse, Large B-cell LymphomaLarge-Cell Lymphoma, DiffuseLymphoma, Diffuse Large-Cell+1 more
Withdrawn

All 7 trials loaded